- Home
- JANX vs JBGS Comparison
JANX vs JBGS Comparison
Compare JANX & JBGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JANX | JBGS |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 823.7M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | JANX | JBGS |
|---|---|---|
| Price | $17.54 | $11.92 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 18 | 3 |
| Target Price | ★ $33.81 | $12.00 |
| AVG Volume (30 Days) | 751.0K | ★ 785.4K |
| Earning Date | 11-09-2026 | 11-10-2026 |
| Dividend Yield | N/A | ★ 5.83% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,000,000.00 | ★ $498,598,000.00 |
| Revenue This Year | $194.24 | N/A |
| Revenue Next Year | N/A | $2.61 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.12 | $9.93 |
| 52 Week High | $35.34 | $19.13 |
Technical Indicators
Market Signals| Indicator | JANX | JBGS |
|---|---|---|
| Relative Strength Index (RSI) | 51.36 | 62.89 |
| Support Level | $15.90 | $10.83 |
| Resistance Level | $19.16 | $12.77 |
| Average True Range (ATR) | 0.83 | 0.35 |
| MACD | 0.07 | 0.13 |
| Stochastic Oscillator | 48.72 | 85.66 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in, and develops real estate assets concentrated in amenity-rich, metro-served submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily, and third-party real estate services. It generates maximum revenue from the commercial segment.